Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02160 CARDIOFLOW-B
RTNominal up1.130 +0.070 (+6.604%)
Others

09/06/2021 17:54

{I-bank focus}Credit Suisse starts CardioFlow at HK$21

[ET Net News Agency, 9 June 2021] Credit Suisse initiated coverage on MicroPort
CardioFlow Medtech (02160) with an "outperform" rating and a target price of HK$21.
The research house said the CardioFlow sales team can leverage MicroPort's (00853) sales
team to penetrate the market in China. In the ex-China market, CardioFlow's sales and
marketing teams can leverage MicroPort's global brand awareness.
Meanwhile, Credit Suisse expects VitaFlow II to be a large revenue contributor in the
TAVR segment in the long term, as the second-generation device has the added functionality
of retrievability, which would allow physicians to perform TAVR procedures with a lower
risk. It expects the success rate adjusted TAVR/TMV revenue contribution to account for
64%/24% of the total sales and reach Rmb5bn/Rmb1.9bn. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.